Dechra Announces Innovative First In Equine Anaesthesia
The first and only equine benzodiazepine1 licensed for the intravenous co-induction of anaesthesia in horses has been unveiled by Dechra Veterinary Products.
Dormazolam®, the first veterinary licensed midazolam (5mg/ml), works in synergy with other induction agents to provide an extended duration of anaesthesia without adversely affecting the quality of recovery2,3,5.
It has been introduced as part of Dechra’s extensive equine anaesthesia solutions range.
Benzodiazepines are commonly incorporated into anaesthetic regimens to alleviate issues seen with the administration to ketamine alone2,3,4, including inadequate muscle relaxation234, anaesthesia not lasting long enough2 and induction failure2.
Despite the issues caused by the sole use of ketamine, it remains the primary anaesthetic induction agent of choice for more than 90% of equine veterinarians2.
Dechra Brand Manager Emma Jennings said: “Using Dormazolam as part of an equine anaesthesia protocol will give optimal general anaesthetic conditions every time, including a rapid onset of action1.
“Anaesthetic co-induction with ketamine and midazolam has been shown to provide a superior quality of anaesthesia compared to ketamine alone3 and midazolam is equally as effective as diazepam when used as a co-induction agent alongside ketamine4. It also cuts down on the number of ketamine ‘top-up’ doses required compared to using ketamine3 alone.
“Additional benefits include no clinically significant differences in cardiopulmonary function1 or recovery times1 between midazolam and diazepam and it can be mixed in the same syringe as ketamine for ease of use4.”
Emma added: “The introduction of Dormazolam provides an exciting new option for equine vets. It delivers enhanced anaesthetic and surgical conditions by improving anaesthetic induction quality2,3,4 and giving better surgical relaxation scores2,3,4. It also reduces involuntary movements because, as a co-induction agent, midazolam only causes minimal cardiovascular and pulmonary depression2,4.”
Dormazolam is available in a 20 ml vial. It has a shelf life of four years and a broached shelf life of 28 days.
For more information about Dormazolam and how it can be used in partnership with Dechra’s equine anaesthesia app, go to www.dechra.co.uk/therapy-areas/equine/anaesthesia/analgesia.
More from Dechra
- New Equisolon® sachets make for convenient dosing for equine asthma
- Exploring the “good, bad and the ugly” of equine lameness diagnosis and treatment
- Dechra’s equine webinar series to provide insight for veterinary professionals
- Canaural® returns to Dechra offering
- Apovomin® provides sickness solution for dogs